Cite
HARVARD Citation
Lukin, D. et al. (n.d.). DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. Journal of Crohn's and colitis. p. S036. [Online].